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Summary: Nivolumab is a feasible therapy option in patients with
advanced non–small cell lung cancer (NSCLC) who progress on
first-line treatment. However, there is limited information about an
overlapping toxicity of PD-1 inhibitors when administered follow-
ing thoracic radiotherapy (TRT). Three of 25 patients with
advanced NSCLC were treated with palliative or curative intent.
Nivolumab was initiated as second or third-line therapy after TRT
for recurrent or progressive disease. All 3 patients developed grade 3
pneumonitis at some point during nivolumab therapy. Herein, we
describe 3 cases of pneumonitis in patients with NSCLC started on
nivolumab following TRT. Imaging analysis was strongly consistent
with heterogenous lung parenchyma changes in the irradiated lung
volume receiving a total dose of 15–20Gy. Pulmonary toxicity was
manageable; however, interruption of immunotherapy was
necessary.
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Nivolumab is an effective, feasible treatment option inadvanced non–small cell lung cancer (NSCLC). On the
basis of CheckMate 0171 and CheckMate 057,2 nivolumab
was approved as second-line standard, unrestricted for use
independent of PD-L1 status.
Because of potential overlapping pulmonary toxicity, a
combination of immunotherapy and thoracic radiotherapy
(TRT) is an important point of clinical investigation. A
meta-analysis on the risk of pneumonitis associated with
immunotherapy reported a relatively low incidence of all-
grade (2.9%) and high-grade (1.8%) pulmonary toxicity,
respectively. The incidence of pneumonitis was higher in
nonmelanoma patients.3 However, a phase I dose-escalation
cohort expansion trial (CA209-003) of nivolumab docu-
mented higher pneumonitis rates in 129 NSCLC patients
with previous TRT. There were 7% and 1.3% of all-grade
and grade 3–4 pneumonitis, respectively.4,5 Herein, we
describe 3 cases of severe pneumonitis in irradiated lungs of
pretreated NSCLC patients on nivolumab.
CASE 1
A 66-year-old female patient (exsmoker) with performance
status (PS) Eastern Cooperative Oncology Group (ECOG) 1 was
diagnosed with squamous NSCLC cT3cN2cM0 (UICC seventh
edition). Radical surgery was performed after 4 cycles of neo-
adjuvant cisplatin/vinorelbine. Four weeks later, postoperative
radiotherapy was delivered to a total dose of 50.0 Gy. The lung
dose-volume histogram parameters were as follows: V20 (both
lungs) 16% (519mL), mean lung dose (MLD) 11.85Gy (Fig. 1A2).
On recurrence, the patient was started on nivolumab. Shortly after
the first cycle, she developed grade 3 dyspnea. High-resolution chest
computed tomography (CT) showed a patchy consolidation
(Fig. 1A4). No pathologic findings were observed on bronchoscopy.
Broncho-alveolar lavage (BAL) showed 60.6% macrophages, 9.3%
lymphocytes, and 30% neutrophils. Microbiological analysis of
BAL was negative. Corresponding changes in pulmonary function
tests (PFTs) before and after the onset of pneumonitis are shown in
Table 1. Immunotherapy was interrupted and the patient was
started on corticosteroids tapered slowly over 5 weeks.
CASE 2
A 76-year-old male patient (nonsmoker) with PS ECOG 1
presented with oligometastatic NSCLC cT1cN2cM1b (UICC sev-
enth edition) and received stereotactic radiosurgery for 2 brain
lesions. Thereafter, 2 cycles of chemotherapy with cisplatin/peme-
trexed followed. PET/CT showed partial remission (Fig. 1B1),
concurrent chemoradiotherapy with cisplatin/pemetrexed to a total
dose of 66.0 Gy was delivered. The lung dose-volume histogram
parameters were as follows: V20 (both lungs) 22% (930mL) and
MLD 12.3 Gy, respectively (Fig. 1B2). Four months later, the
patient presented with metastatic disease and was started on nivo-
lumab. Shortly after the fourth application, he developed grade 3
dyspnea requiring immediate hospitalization, chest CT showed
irregular ground-glass opacities with bilateral fibrotic changes
(Fig. 1B4), BAL showed 9.6% macrophages, 5.6% lymphocytes,
84.6% neutrophils. Microbiological analysis of BAL was negative.
The corresponding changes in PFTs before and after the onset of
pneumonitis are illustrated in Table 1. Immunotherapy was inter-
rupted and the patient was started on 50mg prednisolone tapered
off 5 mg every 4 days over 6 weeks.
CASE 3
A 56-year-old female patient (nonsmoker) with PS ECOG 1
was diagnosed with stage IV NSCLC with multiple brain meta-
stases. She was initially treated with 5 cycles of cisplatin/pemetrexed
and responded well, exhibiting partial remission. Three weeks later,
she underwent palliative irradiation to the brain and thorax. V20
(both lungs) and MLD were 18% (380mL) and 9.45Gy, respec-
tively (Fig. 1C2). Three months later, docetaxel/nintedanib was
initiated due to progressive disease; however, the patient developed
adrenal metastasis and was started on nivolumab. Restaging scans
after 6 cycles revealed diffuse consolidations in both upper lobes
(Fig. 1C4). The patient presented with grade 3 dyspnea also
requiring immediate hospitalization. BAL revealed bronchial epi-
thelial cells with macrophages and neutrophils. Microbiological
analysis of BAL was negative. For changes in the PFTs see Table 1.
Nivolumab was interrupted and treatment with 60mg prednisolone
was started, tapered off 5 mg every 4 days for 6 weeks.
Received for publication July 25, 2017; accepted October 22, 2017.
From the *Department of Radiation Oncology, University Hospital,
LMU Munich; and †Comprehensive Pneumology Center Munich
(CPC-M), Munich, Germany.
F.M. and O.R. contributed equally to this work.
Presented in part at the seventh edition of the European Lung Cancer
Conference 2017 (ELCC 2017), which took place from May 5 to 8,
2017, in Geneva, Switzerland.
Reprints: Chukwuka Eze, Department of Radiation Oncology, Uni-
versity Hospital, LMU Munich, Marchioninistrasse 15, Munich
81377, Germany (e-mail: chukwuka.eze@med.uni-muenchen.de).
Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
CLINICAL STUDY
96 | www.immunotherapy-journal.com J Immunother  Volume 41, Number 2, February/March 2018
Copyright r 2018 Wolters Kluwer Health, Inc. All rights reserved.
DISCUSSION
On the basis of several randomized trials, monotherapy
with nivolumab is becoming an established standard in
NSCLC patients who progress on/after first-line
treatment.1,2 Phase II and III trials investigating the feasi-
bility of nivolumab concomitantly or as consolidation after
chemoradiotherapy in stage III NSCLC are underway
(NICOLAS-ETOP,6 RTOG 3505).
Importantly, the potential overlapping of pulmonary
toxicity of nivolumab and TRT is still unclear. The latest
review on this issue cited only 2 case reports. Moreover, a
recently published piece by Shibaki et al7 described a
similar phenomenon of radiation recall pneumonitis in 2
patients previously treated with TRT 2 years before
immunotherapy. Because of paucity of data in this sce-
nario, final conclusions cannot be drawn.8 The majority of
studies on combined immunoradiotherapy referred to
patients with melanoma treated with intracranial stereo-
tactic radiosurgery.9,10 Lu and Liu11 recently reported on 3
cases of pneumonitis in patients with melanoma, thymoma,
FIGURE 1. A–C, Diagnostic, radiotherapy and follow-up computed tomography (CT) imaging.
TABLE 1. PFTs Before and After Onset of Pneumonitis
PFT Pretreatment PFT 1mo After TRT 5 mo After TRT
Case 1 VC max: 3.14 (120.2%) VC max: 3.28 (125.5%) VC max: 2.56 (98.8%)
FEV1: 1.64 (78.1%) FEV1: 1.77 (84.3%) FEV1: 1.46 (70.7%)
DLCO SB: 2.38 (33.3%) DLCO SB: 2.91 (40.6%) DLCO SB: 1.93 (27.1%)
DLCO/VA: 0.56 (37%) DLCO/VA: 0.62 (41.3%) DLCO/VA: 0.53 (35.6%)
Pretreatment PFT 2mo after TRT 7mo after TRT 8mo after TRT
Case 2 VC max: 4.73 (111.8%) VC max: 4.13 (97.7%) VC max: 3.31 (78.7%) VC max: 4.03 (95.9%)
FEV1: 2.80 (91%) FEV1: 2.49 (81.1%) FEV1: 2.57 (84.5%) FEV1: 2.72 (89.2%)
DLCO SB: 5.06 (56.1%) DLCO SB: 3.13 (34.7%) DLCO SB: 1.85 (20.7%) DLCO SB: 2.69 (30%)
DLCO/VA: 0.87 (70.8%) DLCO/VA: 0.56 (45%) DLCO/VA: 0.41 (33.2%) DLCO/VA: 0.48 (39.3%)
Pretreatment PFT 2mo after TRT 11mo after TRT 14mo after TRT
Case 3 VC max: 2.99 (92.57%) VC max: 3.05 (94.43%) VC max: 2.24 (70%) VC max: 2.31 (72.2%)
FEV1: 2.21 (83.1%) FEV1:2.27 (85.34%) FEV1: 1.72 (65.15%) FEV1: 1.70 (64.4%)
DLCO SB: 3.58 (43.08%) DLCO SB: 3.64 (43.8%) DLCO SB: 2.88 (34.87%) DLCO SB: 2.67 (32.32%)
DLCO/VA: NA DLCO/VA: NA DLCO/VA: NA DLCO/VA: NA
DLCO indicates diffusion capacity of the lungs for carbon monoxide; NA, not available; PFT, pulmonary function test; SB, single breath; TRT, thoracic
radiotherapy; VA, alveolar volume; VC, vital capacity.
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and jejunal adenocarcinoma treated with PD-1 inhibitors
and radiotherapy.
Previous results, including a meta-analysis detected a
very low incidence of immune-related pneumonitis in
patients treated with PD-1 inhibitors.1–3 In contrast, a phase
I dose-escalation cohort expansion trial (CA209-003) of
nivolumab including 129 NSCLC patients pretreated with
TRT revealed a 7% incidence of all grade pneumonitis.4,5 In
addition, a recent phase II study presented at ASCO 2016
showed an incidence of 20.5% for all grade and 3.6% for
grade 3–5 pneumonitis in patients treated with consolidation
pembrolizumab initiated 1–2 months following concurrent
chemoradiotherapy.12
Furthermore, in a recent meta-analysis, grade 5 pneu-
monitis was described in seven patients treated with PD-1
inhibitors. Three of these patients were treated with thoracic
radiotherapy before PD-1 inhibitors.13 On the basis of this
data, a higher risk for immune-related pulmonary toxicity in
this patient cohort can be supposed.
Herein, we presented a case study with grade 3
pneumonitis in the irradiated lungs of pretreated NSCLC
patients undergoing immunotherapy. In all cases, exten-
sive imaging and bronchoscopy were performed on onset
of respiratory symptoms. Nivolumab was interrupted and
all patients were started on corticosteroids for the fol-
lowing 5 to 6 weeks with relatively rash alleviation of
symptoms. Median time from the end of TRT to mani-
festation of pneumonitis was 167 days indicating an
importance of careful follow-up for early signs and
symptoms of pneumonitis throughout successive treatment
with immune-checkpoint inhibitors. Extensive imaging
analysis was strongly consistent with broadly based
parenchyma changes in the irradiated lung volume
receiving 15–20 Gy. A relatively low MLD and the timing
of the onset of pneumonitis in all 3 cases, makes a case
against sole radiation-induced lung injury (RILI).14
However, a synergistic effect of TRT on immune-related
pneumonitis or counterpart nivolumab effect on the
induction of RILI could not be excluded.
Clinical and fundamental research of pneumonitis and
RILI is urgently required. Despite the ever-increasing
continuous application of immunotherapy prior and following
TRT in patients with advanced lung cancer, there has not
been much progress in the investigation of immunological
aspects of immunotherapy-induced and radiation-induced
lung injury. Our case study underscores the importance of this
problem. Table 2 displays a summary of the current evidence
on the incidence of pneumonitis in various reports and studies.
In conclusion, in our current study all 3 patients ach-
ieved a durable response; however, this was at the cost of
severe pulmonary toxicity, which was manageable in all
cases. A detailed analysis of the described overlapping tox-
icity in pretreated NSCLC patients will be performed within
the scope of a planned single-center prospective trial.
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Type Stage TRT Immunotherapy
Concurrent
vs. Sequential Pneumonitis Rate






Sequential All patients after 4 cycles
Miyoshi et al15 1 Case
report






NSCLC — Yes PD-1 and PD-L1
inhibitors
Sequential The incidence of any grade pneumonitis
was significantly higher with PD-1
inhibitors than with PD-L1 inhibitors
(3.6%, 95% CI, 2.4%–4.9% vs. 1.3%,
95% CI 0.8%–1.9%)
Grade 5 pneumonitis in 7, 3 of these
patients treated with radiation
CA 209-0034,5 129 Phase I NSLCC — Yes Nivolumab Sequential 7% for all-grade pneumonitis
1.3% for grade 3–4 pneumonitis
Shibaki et al7 2 Case
report







NSCLC III Yes Pembrolizumab Sequential 20.5% any grade pneumonitis
3.6% grade 3–5 pneumonitis
CI indicates confidence interval; NSCLC, non–small cell lung cancer; TRT, thoracic radiotherapy.
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